Latest & greatest articles for testosterone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on testosterone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on testosterone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for testosterone

61. Incomplete testosterone suppression in prostate cancer.

Incomplete testosterone suppression in prostate cancer. Incomplete testosterone suppression in prostate cancer. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 21067409 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2010 Nov 11;363(20):1976. doi: 10.1056/NEJMc1010187. Incomplete testosterone suppression in prostate cancer. , . PMID: 21067409 DOI: [Indexed for MEDLINE] Free full text Publication type MeSH terms Substances Full Text Sources Medical Miscellaneous PubMed Commons 0 comments How to cite this comment: Supplemental Content Full text

NEJM2010

62. Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis

Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, Agrwal N, Elamin MB, Gallegos-Orozco JF, Wang AT, Erwin PJ, Bhasin S, Montori VM CRD summary This review concluded that although haemoglobin (...) and haematocrit increased and high density lipoprotein cholesterol decreased in men who received testosterone therapy, the clinical significance of these findings was unclear and the evidence base was deficient. The review had some limitations, but the authors were appropriately cautious regarding the reliability of the results given the limitations of the original studies. Authors' objectives To determine the adverse events associated with testosterone therapy in adult men. Searching MEDLINE, EMBASE

DARE.2010

63. Adverse events associated with testosterone administration.

Adverse events associated with testosterone administration. 20592293 2010 07 21 2010 07 27 2016 12 07 1533-4406 363 2 2010 Jul 08 The New England journal of medicine N. Engl. J. Med. Adverse events associated with testosterone administration. 109-22 10.1056/NEJMoa1000485 Testosterone supplementation has been shown to increase muscle mass and strength in healthy older men. The safety and efficacy of testosterone treatment in older men who have limitations in mobility have not been studied (...) . Community-dwelling men, 65 years of age or older, with limitations in mobility and a total serum testosterone level of 100 to 350 ng per deciliter (3.5 to 12.1 nmol per liter) or a free serum testosterone level of less than 50 pg per milliliter (173 pmol per liter) were randomly assigned to receive placebo gel or testosterone gel, to be applied daily for 6 months. Adverse events were categorized with the use of the Medical Dictionary for Regulatory Activities classification. The data and safety

NEJM2010 Full Text: Link to full Text with Trip Pro

64. Axiron (testosterone) topical solution

Axiron (testosterone) topical solution Drug Approval Package: Axiron (testosterone) NDA #022504 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Axiron (testosterone) topical solution Company: Acrux Pharma Pty Ltd. Application No.: 022504 Approval Date: 11/23/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

FDA - Drug Approval Package2010

65. Fortesta (testosterone) Gel for topical use

Fortesta (testosterone) Gel for topical use Drug Approval Package: Fortesta (testosterone) NDA #021463 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Fortesta (testosterone) Gel for topical use, 10 mg of testosterone per pump actuation Company: Endo Pharmaceuticals, Inc. Application No.: 021463 Approval Date: 12/29/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF

FDA - Drug Approval Package2010

66. The Effect of Testosterone on Metabolic Syndrome and Type 2 Diabetes

The Effect of Testosterone on Metabolic Syndrome and Type 2 Diabetes "The Effect of Testosterone on Metabolic Syndrome and Type 2 Diabetes" by Alison Quammen < > > > > > Title Author Date of Award 8-14-2010 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Mary Von PA-C Second Advisor Annjanette Sommers MS, PAC Third Advisor Rob Rosenow PharmD, OD Rights . Abstract Background: Metabolic syndrome (MetS) and diabetes type 2 (DM2 (...) a link between hypogonadism and metabolic syndrome and the next step is to evaluate if raising a man’s testosterone levels back to physiologic norms has any benefit in the treatment of metabolic syndrome or DM2. Methods: A comprehensive review of the literature was performed using the data bases: CINAHL, ovid - Medline, EBMR Multifile, Web of Science, PubMed and Google scholar. This produced a number of studies and the following exclusion criteria were applied to limit the search. Exclusion criteria

Pacific University EBM Capstone Project2010

67. Effects of testosterone replacement in middle-aged men with dysthymia: a randomized, placebo-controlled clinical trial

Effects of testosterone replacement in middle-aged men with dysthymia: a randomized, placebo-controlled clinical trial 19440073 2009 05 14 2009 08 03 2015 11 19 1533-712X 29 3 2009 Jun Journal of clinical psychopharmacology J Clin Psychopharmacol Effects of testosterone replacement in middle-aged men with dysthymia: a randomized, placebo-controlled clinical trial. 216-21 10.1097/JCP.0b013e3181a39137 Mid-life onset male dysthymic disorder (DD) seems to be a distinct clinical condition (...) with limited therapeutic options. Testosterone replacement is mood-enhancing and has been proposed as an antidepressant therapy, though this strategy has received limited systematic study. We therefore conducted a six-week double-blind placebo-controlled clinical trial in 23 men with DD and with low or low-normal testosterone (T) level (i.e, screening total serum testosterone <350 ng/dL). Enrolled men were randomized to receive intramuscular injections of 200 mg of testosterone cypionate or placebo every

EvidenceUpdates2009

68. Testosterone undecanoate (Nebido) - Testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests

Testosterone undecanoate (Nebido) - Testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests

Scottish Medicines Consortium2009

69. Testosterone and depression: systematic review and meta-analysis

Testosterone and depression: systematic review and meta-analysis Testosterone and depression: systematic review and meta-analysis Testosterone and depression: systematic review and meta-analysis Zarrouf FA, Artz S, Griffith J, Sirbu C, Kommor M CRD summary This review concluded that testosterone replacement therapy may have an antidepressant effect, especially for patients who also have hypogonadism or HIV infection. Limitations in the review methods and the evidence base suggest (...) that the conclusions should be treated with caution. The conclusions are unlikely to be applicable to the general population of patients with depression. Authors' objectives To evaluate the effect of testosterone administration on depression. Searching The authors searched MEDLINE, the Clinical Trials Registry and the Cochrane Central Register of Controlled Trials (CENTRAL) from inception to February 2008. The search was limited to English language publications. Search terms were reported. Reference lists were

DARE.2009

70. Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review

Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review Shabsigh R, Crawford E D, Nehra A, Slawin K M CRD summary The authors concluded that there was no evidence that testosterone treatment in men with hypogonadism increased the risk of prostate cancer. The authors (...) ’ conclusions appeared to reflect review findings, but the lack of reporting of review methods and study quality and reliance upon generally small short-term studies meant that they may not be robust. Authors' objectives To determine if testosterone therapy for hypogonadism in men increases the risk of prostate cancer. Searching MEDLINE and EMBASE were searched from 1970 through 2008 for studies published in English. Search terms were reported. References in journal articles, conference proceedings

DARE.2009

71. Testosterone for low sexual desire in surgically postmenopausal women

Testosterone for low sexual desire in surgically postmenopausal women Testosterone for low sexual desire in surgically postmenopausal women Testosterone for low sexual desire in surgically postmenopausal women Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Report may be purchased from . Citation Testosterone for low sexual desire in surgically postmenopausal women (...) . Lansdale: HAYES, Inc.. 2009 Authors' objectives Administration of exogenous testosterone has been investigated as a treatment for low sexual desire in women. Endogenous androgens, produced in women by the ovaries, adrenal glands, and peripheral tissue, are thought to play a role in the regulation of sexual desire. In women in whom both ovaries are removed (bilateral oophorectomy), testosterone levels drop substantially and sexual desire may be reduced. Although the precise relationship between

Health Technology Assessment (HTA) Database.2009

72. Testosterone for low sexual desire in premenopausal women

Testosterone for low sexual desire in premenopausal women Testosterone for low sexual desire in premenopausal women Testosterone for low sexual desire in premenopausal women Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Report may be purchased from . Citation Testosterone for low sexual desire in premenopausal women . Lansdale: HAYES, Inc.. 2009 Authors' objectives (...) Administration of exogenous testosterone has been investigated as a treatment for low sexual desire in women. Endogenous androgens, produced in women by the ovaries, adrenal glands, and in peripheral tissue, are thought to play a role in the regulation of sexual desire. Although the precise relationship between testosterone levels and sexual desire in women is not clear, the goal of testosterone therapy is to increase sexual desire. Project page URL Indexing Status Subject indexing assigned by CRD MeSH

Health Technology Assessment (HTA) Database.2009

73. Short-term testosterone augmentation in male schizophrenics: a randomized, double-blind, placebo-controlled trial

Short-term testosterone augmentation in male schizophrenics: a randomized, double-blind, placebo-controlled trial 18626263 2008 07 15 2008 10 24 2013 11 21 1533-712X 28 4 2008 Aug Journal of clinical psychopharmacology J Clin Psychopharmacol Short-term testosterone augmentation in male schizophrenics: a randomized, double-blind, placebo-controlled trial. 375-83 10.1097/JCP.0b013e31817d5912 Although there are few studies on the treatment of schizophrenia with testosterone, several indirect (...) findings have suggested testosterone as a possible treatment modality for schizophrenia. To explore the therapeutic effect of testosterone augmentation of antipsychotic medication on symptoms in male patients with schizophrenia, the authors performed a placebo-controlled, double-blind trial on 30 schizophrenic men, using either 5 g of 1% testosterone gel (Testogel; Besins Iscovesco, Paris, France) or a placebo added to a fixed dosage of antipsychotic medication over a period of 4 weeks with a 2-week

EvidenceUpdates2008

74. Testosterone supplementation did not prevent cognitive decline or increase bone mineral density in older men

Testosterone supplementation did not prevent cognitive decline or increase bone mineral density in older men Testosterone supplementation did not prevent cognitive decline or increase bone mineral density in older men | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Testosterone supplementation did not prevent cognitive decline or increase bone mineral density in older men Article Text Therapeutics Testosterone supplementation did not prevent cognitive decline or increase bone mineral density in older men Statistics from Altmetric.com No Altmetric data available

Evidence-Based Medicine (Requires free registration)2008

75. Testosterone for low libido in postmenopausal women not taking estrogen.

Testosterone for low libido in postmenopausal women not taking estrogen. 18987368 2008 11 06 2008 11 24 2013 11 21 1533-4406 359 19 2008 Nov 06 The New England journal of medicine N. Engl. J. Med. Testosterone for low libido in postmenopausal women not taking estrogen. 2005-17 10.1056/NEJMoa0707302 The efficacy and safety of testosterone treatment for hypoactive sexual desire disorder in postmenopausal women not receiving estrogen therapy are unknown. We conducted a double-blind, placebo (...) -controlled, 52-week trial in which 814 women with hypoactive sexual desire disorder were randomly assigned to receive a patch delivering 150 or 300 microg of testosterone per day or placebo. Efficacy was measured to week 24; safety was evaluated over a period of 52 weeks, with a subgroup of participants followed for an additional year. The primary end point was the change from baseline to week 24 in the 4-week frequency of satisfying sexual episodes. At 24 weeks, the increase in the 4-week frequency

NEJM2008

76. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial.

Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. 18167405 2008 01 02 2008 01 10 2016 10 17 1538-3598 299 1 2008 Jan 02 JAMA JAMA Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. 39-52 10.1001/jama.2007.51 Serum testosterone levels decline significantly with aging. Testosterone supplementation to older men might (...) beneficially affect the aging processes. To investigate the effect of testosterone supplementation on functional mobility, cognitive function, bone mineral density, body composition, plasma lipids, quality of life, and safety parameters in older men with low normal testosterone levels. Double-blind, randomized, placebo-controlled trial of 237 healthy men between the ages of 60 and 80 years with a testosterone level lower than 13.7 nmol/L conducted from January 2004 to April 2005 at a university medical

JAMA2008

78. Testosterone for schizophrenia.

Testosterone for schizophrenia. BACKGROUND: Recently, sex hormones such as estrogens and testosterone or its derivatives have been the focus of interest for treatment of persistent symptoms associated with schizophrenia. OBJECTIVES: To review the effects of dehydroepiandrosterone (DHEA)/testosterone as adjunctive therapy to standard antipsychotic drugs. SEARCH STRATEGY: We searched the Cochrane Schizophrenia Group Trials Register (January 2007). SELECTION CRITERIA: We included all clinical (...) randomised trials comparing DHEA/testosterone plus standard antipsychotic treatment with standard treatment alone. DATA COLLECTION AND ANALYSIS: We independently selected studies and extracted data. For dichotomous data we calculated the relative risk (RR) and its 95% confidence interval (CI) on an intention to treat basis, using a fixed effects model. We presented continuous data using the weighted mean difference statistic, with a 95% confidence interval using a fixed effects model. MAIN RESULTS: We

Cochrane2007

79. Testosterone 2% gel (Tostran)

Testosterone 2% gel (Tostran) Scottish Medicines Consortium testosterone 2% gel (Tostran®) (No. 372/07) ProStrakan Product Update 6 April 2007 (Issued May 2007) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission testosterone 2% gel (Tostran®) is accepted for restricted use (...) within NHS Scotland for replacement therapy with testosterone for male hypogonadism when testosterone deficiency has been confirmed by clinical symptoms and laboratory analyses. It is an alternative to other formulations of testosterone gel, with similar costs for equivalent doses. It is restricted to use as an alternative to testosterone patches for those patients requiring a transdermal delivery system. Testosterone gel is at least as effective as testosterone patches and costs less. Advice context

Scottish Medicines Consortium2007